Adjunctive Rifampin Not Beneficial for Staph aureus Bacteremia Adjunctive Rifampin Not Beneficial for Staph aureus Bacteremia

Adjunctive rifampin, also called rifampicin, provides no significant benefit over standard antibiotic therapy in patients with Staphylococcus aureus bacteremia, according to results from the ARREST trial.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news